Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir. Derived from Wikipedia licensed CC-BY-SA.
Open Access statistics for Gilead Sciences (United States), United States, covering academic research published from 2000 to 2023. Read More.
Open Access Percentage
61%
Total
Publications
5K
Total Open
Publications
3.1K
Total
Citations
233K
Open Access
Percentage
61%
Total
Publications
5K
Total Open
Publications
3.1K
Total
Citations
233K
Breakdown
Publisher Open
23%
Both
26%
Other Platform Open
12%
Closed
39%
Percentage of Open Access over time
Publisher Open
Both
Other Platform Open
Closed
Volume of Open Access over time
Open
Closed
Publisher Open
OA Journal 28%
695
Hybrid 31%
752
No Guarantees 41%
1K
Other Platform Open
Domain 87%
1.7K
Institution 25%
482
Other Internet 9%
165
Public 7%
142
Preprint 6%
106
Other Platform Locations
Name | Platform Type | Publications |
---|---|---|
PubMed Central | Domain | 1.7K |
Europe PMC | Domain | 987 |
Semantic Scholar | Public | 115 |
DOI | Other Internet | 80 |
California Digital Library - eScholarship | Other Internet | 62 |
University of California - eScholarship University of California | Institution | 59 |
University College London - UCL Discovery | Institution | 58 |
bioRxiv | Preprint | 52 |
University of North Carolina at Chapel Hill - Carolina Digital Repository | Institution | 51 |
Figshare | Public | 34 |